Skip to main content

Table 1 Baseline characteristics of study population

From: Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study

  Total (N = 573) Recent cocaine/crack use (N = 211) Previously used cocaine/crack; not recent (N = 290) Never used cocaine/crack (N = 72)
Follow-up time (years)a 2.3 (1.0, 4.1) 2.1 (1.0, 3.9) 2.4 (1.1, 4.5) 2.0 (0.8, 4.4)
Age (years) 44 (38, 49) 43 (38, 49) 44 (38, 48) 47 (40, 53)
Female 173 (30%) 69 (33%) 81 (28%) 23 (32%)
Aboriginal 86 (15%) 53 (25%) 31 (11%) 2 (3%)
Time since HIV diagnosis (years) 10 (5, 16) 10 (5, 14) 10 (6, 16) 13 (5, 20)
Duration HCV infection (years) 18 (10, 25) 19 (12, 26) 18 (11, 25) 10 (4, 20)
CD4 cell count (cells/μL) 389 (253, 550) 360 (220, 528) 390 (260, 550) 439 (300, 601)
HIV RNA load ≤ 50 copies/mL 340 (59%) 117 (55%) 175 (60%) 48 (67%)
Time since first start of ART (years) 6 (2, 11) 6 (2, 10) 6 (3, 11) 9 (2, 12)
cART regimen 453 (79%) 164 (78%) 227 (78%) 62 (86%)
Prior AIDS diagnosis 162 (28%) 65 (31%) 77 (27%) 20 (28%)
APRI 0.5 (0.4, 0.8) 0.5 (0.4, 0.7) 0.6 (0.4, 0.8) 0.6 (0.4, 1.0)
HCV RNA (log10 UI/mL)b 6.2 (5.4, 6.7) 6.1 (5.1, 6.6) 6.2 (5.5, 6.8) 6.2 (5.6, 6.7)
HCV treatment naïve 512 (89%) 197 (93%) 258 (89%) 57 (79%)
Alcohol abusec 83 (14%) 41 (19%) 37 (13%) 5 (7%)
  1. a: Median (IQR) or Number (%)
  2. b: For HCV RNA only 307 (86/211 (41%) recent cocaine/crack users, 170/290 (59%) previous/not recent cocaine/crack users, and 51/72 (71%) non cocaine/crack users) had available quantitative HCV RNA values
  3. c: Defined as >6 drinks at least once a month and >2 drinks on a typical day when drinking